Episode Description
- A 2022 meta-analysis of 37 randomized trials found that berberine lowered glycated hemoglobin by 0.63% and fasting glucose by 0.82 mmol/L, with consistent results across diverse patient groups
- Earlier researchers also highlighted how berberine lowers blood sugar and harmful blood fats while also reducing liver fat and markers linked to kidney damage
- Berberine limits fat cell development and dampens inflammation as well, effects that may support weight control and improved insulin sensitivity
- In a 13‑week randomized study, researchers showed that berberine's blood sugar-lowering abilities are on par with the effects of the diabetes drug metformin
- Clinical studies support taking 500 mg of berberine with meals up to three times daily, starting with lower doses and increasing gradually; however, there are safety precautions to keep in mind